0QAJ.LSE DBV Technologies

Healthcare Commercial Services & Supplies London Exchange
- EUR
Market cap
-
P/E
-
P/B
-
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2022.

Is 0QAJ.LSE undervalued?

Graham number

The Graham number of DBV Technologies cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

DBV Technologies fundamental analysis

No fundamental analysis for DBV Technologies yet.

DBV Technologies stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About DBV Technologies

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.…

Full company profile